secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001193805-24-001318
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan
--------------------------------------------------------------------------------

- Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).
- Cash $294.1M; runway extended through Q1 2027. Total $462.1M in upfront and milestone payments from CSL to date.
- $25M commercial milestone triggered by first sale of KOSTAIVE in Japan by Meiji Seika Pharma in September.
- ARCT-032 CF and ARCT-810 OTC deficiency Phase 2 interim proof-of-concept data expected in first half of 2025.
- European CHMP opinion for KOSTAIVE expected December 2024; U.S. BLA filing planned in H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524001318/0001193805-24-001318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524001318/e663993_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-001318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer